on revenue, adjusted sixth straight enters quarter Elanco with Farm Thanks, morning, organic Animal pleased our Health both and report line We're currency an Tiffany. X% our to constant growth all Good across businesses. everyone. with of EPS leverage in growth, momentum. adjusted Fourth were XXXX basis, net quarter Pet EBITDA, and our up with expectations. revenue
constant revenue pet XXXX, from step Health us Animal, U.S. our well a represents the from several growth market stabilizing XXXX. hold position of global to of where durability gains share leadership positions. innovation, driven the in up for retail Pet in both XXXX which and open X% presence. Farm into want reflects I balanced highlighting importantly, our geographic portfolio diverse a and year, accomplishments by accelerating Farm and pricing by Animal XXXX and That X% currency growth organic meaningful and growth base, and full we
we countries. across our Additionally, XX and line broad-based top top in top X franchises of currency X our constant experienced product growth organic
our of Through have commercial global potential markets, execution blockbusters the We exceeded revenue XXXX. portfolio with in innovation diverse now target X focused we launched our innovation market. for across
range We for confidence XXXX, our new the have these in from the raised continued reflecting also products. contributions
focus operating than Additionally, pay launches. sale aqua in divesting on investments strategic debt cash strategic support in our increased XX% XXXX, The we opportunities, of and allowed our $X.X concentrated business. billion us flow more and product our impact with combined our successfully approximately to highest the proceeds down
the value we drivers X XXXX, When started we growth, cash. for and innovation highlighted Elanco,
launched innovation on We cash key our all exceeded while growth, have products, year front. delivering made accelerated plan, strong We progress of operating flow. biggest our each X yet
to Looking cash remain priorities and proposition. value our the to expand XXXX, growth, innovation
an to We of currency acceleration in growth constant anticipate organic continue X%. X% revenue to
X%. Excluding aqua and grow adjusted to expect to the the we anticipated EBITDA FX X% impacts divestiture, of
other we corporations, our strength broke exchange the dollar. quarter we we our in expansion growth the results impacted contribution guidance. XXXX stabilization XXXX and sustained while should to are the of business, product like over increasing global many With our enable negatively foreign and highlight from of infrastructure base stronger optimized Notably, innovation beyond. X, the on Slide of fourth margin impact On our by time, mix and out and expect business, core
this pleased Our dynamic quarter fundamentals in focused Overall, remain global accelerating in execution, performance full and unchanged. and commercial are backdrop are fourth XXXX. with against team year macroeconomic on confident is expectations essentially underlying our we
currency constant we were stable X, the underlying or more marking X the organic to excludes growth impact performance aqua delivered quarter, divestiture than best in in the on Slide quarter, All prior which Turning areas in fourth X years. down periods. revenue the break growth, X% of our the broad-based
was the value Farm Experior combo reached U.S. began sales Animal cattle. we from up received November heifers comprehensive led Rumensin, status X% in alone, our portfolio. benefiting demonstrating for use blockbuster supported growth the after in the by U.S. This clearance. that FDA from increasing demand of
in Farm the in by model changes global and was impact geographies. Asia. less was improvement driven in the X% Animal economics despite challenging The swine stronger poultry third Different our flat certain International demand sequential from commercial quarter from Do decline
XX%, of efforts now We DTC in million, International robust of growth Pet Health continued strength Seresto. sales Adtab $XXX peak to successful Europe. reflecting expect driven by delivered Adtab and exceed
international across markets, very achieved Asia geography, of a the Latin Pet Health diverse By from contributions Europe, Middle growth Pacific Canada. with range America, and East,
Health U.S. revenue September. launched Pet X%, from grew the Finally, contributions in late Zenrelia, including early which
X% the achieved portfolio in quarter. quarter and XXXX, since third Galliprant our Importantly, results its of posted growth the best vaccine
X/X veterinary lead We and with and of owners retail positive clinics. increased distribution, the serving continue to pet trends who points of the on purchases make share capitalizing market gains outside the
Slide X. to Turning
XXXX, to portfolio result paid leverage ratio to and a productivity, X.Xx a and resulting in company-wide improvement. end direct transaction our or XXXX. the of with productivity year, innovation strategic cash advance down IPP This the we Starting down aqua X.Xx from to start $X.XXX achievement continue the commitment of in debt of conversion a billion was We at strategy. in net
broader Health in of we across a lift pain generate parasiticides, and us incentive are the complete around entire health U.S. innovation allowing animal X offer offer companies a now partners portfolio who growth. our saw plans, and priority markets: Health, key clinics Pet across a a X Pet set with both From portfolio, therapeutics. driving company of In products on cultural leverage the sides created to comprehensive our cash of dermatology, vaccines has other ultimately Vet all XXXX's prioritized pay and durable debt to globe, procurement generation solutions, to business X portfolio. and we to On our our benefits down.
a leadership, recently formulated introduced brands we Pet Building on of OTC supplements. of and the Protect, complete science-backed strength our line retail veterinary advantaged
in our European the leadership underscores in parasiticides. Adtab growth in retail market Health and Pet Additionally, Seresto
U.S. in organic multiple In XXXX, driven million Animal, in $XXX the growth by Farm portfolio species. achieved
Our momentum indicates recent swine we ended data beef, U.S. the the dairy. as in year the good leader poultry, in with market and in
This volume supported carbon enablement in our by growth, flagship inset XX-year-old and driven product, XX% the by revenue Rumensin, value by with dollar Our U.S. full was generated the complementary captured further market in portfolio new up growth the dairy. and
a for disease, respiratory treatment as conveniently Targeted bolster bovine and low-volume Pradalex, innovations shot. portfolio launched Pradalex a we wider important of antimicrobial recently, swine solutions. our given More one medically like
portfolio to The in our bring needs. just review. is to the transmission vaccine emerging And announced even use the we conditional influenza further in We've cross-species solutions vaccines of our agreement for stages with for continue avian dairy disease pleased unmet devastating The high-path boost spreading to customers dairy commercialize dairy. between approval Medgene to final to USDA cattle cattle bring shows be of to nearly are into vaccine herds birds U.S., the this the the to with across A to options transmission, X,XXX Elanco and critical virus will along the disease. needed. is interventions that fight cattle. with slow quickly more partner of Medgene zoonotic
U.S. transformational ] through in spaces. alone. early developments including approvals, markets. robust bring Elanco late-stage recent antibody approvals focused needs Now product that integrated to the a strong and address top market Ellen of an mid-stage progress [ emerging and significant innovation. unmet made consistent her built assets, a positioned on team On team delivered new authorizations differentiated XXXX is and engine innovation on to X flow of a core major of and and well monoclonal her high-impact in deliver to platform have portfolio into
$XXX in we the our million Looking of potential $XXX $XXX full our at million from million. year, X, momentum $XXX revenue Slide fourth With and blockbusters, the million growing $XXX of our X delivered from XXXX. for target quarter surpassing we IL-XX, to by innovation be XXXX This any in are innovation to which contributions does expected expect assume revenue the for to of quarter $XXX fourth we increasing not million. the to USDA million approved
X now in X,XXX dermatology about with X X,XXX the X,XXX and piloting ago, Zenrelia progress used than clinics XX% on U.S. Zenrelia. billion of months we Zenrelia the the on nearly these are market, entered is which starting more the over approximately of blockbusters global use. last demonstrated double-digit total, has double-click Let's vet product adopted and Slide or have decade. $X.X which the fully X, launched growth of robust
Customer the driven reviews have been of value efficacy the and the by product. positive,
to Zenrelia's a feedback can the the prescribe and efficacy XX% and This confidence us growing above growing, as Zenrelia adoption gives clinic is will is will of increasingly first-line in used testament that per as the vets international seen product number as willing we be rate continue markets. launch proposition. reorder success clear value time The treatment to increase, over and and Our the of have use and approach. tech-to-tech demonstrating to time, with
momentum accelerated other reached critical DTC good clinic date with experienced investments milestones penetration, to We've and in program. vet have targeted sampling January. marketing and into We've multichannel our including education and
our proactively pet allergy directly of the value ahead and efficacy, communicating season. We message are owners, of convenience to
labels with Brazil the in launched restrictive January, of U.S., joining Zenrelia than the Outside all in in Canada and U.S. Japan, less
U.K. the Australia this globalization Europe, as We rollout also approvals year of fastest and date. our expect in part to
of differentiators We coverage speed in kill exceeded Now distributor for shipped vet to are from product These our thrilled days uptake, launched differentiation, tapeworm, Again, early initial one. of which ahead Credelio season. response early of are reception, month X but the has resonating we the coverage shifting product heartworm U.S. January, broad clinic with and tick it's dimensions the to adoption and the across for and veterinarians with Quattro. Quattro, parasiticide expectations including
in products our for category tick endectocide, today, space. is And other competitiveness it's vet products our Elanco as that in market notably now Quattro growth the and intestinal it less proposition the cannibalization clinic. in $X.X accretive opportunity parasiticide a Pet Remember U.S. recent of our is with parasite core we than of portfolio with launches see our spectrum significantly Health although nearly endecto fastest-growing early, portfolio market. billion combination meaningful the broad XX% flea, increases representing the U.S. and value
gains, for and we momentum the growth entering blockbuster product for we're efforts the Advantage is by offer share market, encouraged and at In the tick expected is is active cannibalization. Adtab ingredient to peak, The through and achieving and minimal found Adtab that January, brand's now European in In labeled season. DTC we leverages the shared protection also become flea dogs same parasiticide OTC family. and Adtab with both the under robust a cats. Credelio,
our canine balance defending been somewhat treatment. of adoption expected, the this importance initially Health, vital than parvovirus monoclonal as Pet customers cost versus of against antibody deadly out virus Rounding has slower of the puppies
We to continue penetration to accelerate interventions strategic all channels. clinic across explore
conditional approval Additionally, in we Canada end at received of the January.
Animal, we companies. created progress, year, Bovaer's be both Farm and creating billion farmers carbon encouraged market, and inset substantiated economic independent a estimate dairy $X we and carbon Last value consumer cattle In can remain first additive what for good market. by we the product
on-farm proof of in fourth over herd the approximately cows our U.S. in million More footprint. than XX% their a using earned quarter, the interventions $XX first As quantifying point, by their to created solution greenhouse dairy X now in dairy digital to the enabling farmers Elanco's million Rumensin. U.S. reductions credits gas farmers and or enrolled lower to are step emission monetize for UpLook database,
demand We XXXX. with contracted have farmers, buy marketplace a see CPGs credits Bovaer from multiple to and in strong carbon
center the among focused implementation into now product feed on the is and use attention mills. co-ops, bringing of chain the and Our processors value
trajectory expect mill. through by positive state-by-state, farm our mill but by ground to Bovaer's execute We farm, as revenue follow ramp measured a feed we game XXXX feed
larger access benefit Experior the ended significant, over clearance. about blockbuster first a a heifers Farm decade. the The became strong in XXXX note, XX% as market of opening animals. Animal is with feedlot on increased a Experior the comprise of Finally, the heifer U.S.
in in allows to to trajectory XXXX, growth feedlot greater Experior's portfolio and and in its owners the confident U.S. strength. overall proposition strong while price, value Canada are We leveraging increase us
era new comprehensive summary, with this innovation game-changing portfolios. Elanco, and In our is equipped global team entering differentiated for
confidence broadly X mode. in are our commercial all to revenue XXXX. innovation sales market, in indicators X% continued are these Our growth in around Early the in launches we increased blockbusters potential and constant on organic driving expectations to execution currency X% positive, are acceleration and
detail. results in With more over our that, to to outlook I'll hand Todd discuss fourth it quarter and
